 I. To determine the recommended phase 2 dose RP2D of BKM120 PI3K inhibitor BKM120 that can be administered in combination with carboplatin and pemetrexed pemetrexed disodium in patients with advanced non-squamous non-small cell lung cancer NSCLC. 